Excel Industries Ltd

- No specific mention of new fundraising through debt or equity was made during the call. - The Company currently has a strong balance sheet. - Support for planned investments and CAPEX (Rs. 200-300 crores over 3 years) is planned to be largely funded through internal accruals. - No disclosure of new borrowings or equity issuance was indicated at this time. - Any future requirements or disclosures related to fundraising will be communicated as necessary.

- Excel Industries plans to spend Rs. 200 to Rs. 300 crores of CAPEX over the next 3 years covering maintenance, modernization, and growth initiatives. - Annual maintenance and modernization CAPEX is typically Rs. 40 to Rs. 50 crores. - Growth CAPEX will focus on both new product opportunities and strengthening existing product lines, with an emphasis on specialty chemicals. - Rs. 15 crores is allocated for setting up an R&D center for process development and technology innovation. - Asset turnover for future growth CAPEX is expected in the range of 1.25 to 1.5 times. - Internal accruals will largely support these investments, backed by a strong balance sheet. - Capacity expansions include doubling capacity for certain biocides and increasing agrochemical production capabilities.

- FY '25 revenue grew 18% YoY to approx. Rs 978 crores, driven largely by volume growth with some price benefit. - Normal monsoon forecast for India in FY '26 expected to support a normal agrochemical sector year. - Biocides capacity expansion to be completed by H2 FY '26, potentially providing incremental revenue. - Focus on both spot market and strategic product positioning over order book approach. - Plans to spend Rs 200-300 crores CAPEX over 3 years to support growth, including new product launches and capacity expansion. - Continued emphasis on specialty chemicals alongside agrochemicals to diversify revenue mix. - Aim to improve capacity utilization from current 70-75%, with peak possible at 85-90%. - Growth CAPEX expected to target specialty chemicals and adjacent product opportunities. - Anticipation of steady or improving EBITDA margins (13-15%) aligning with growth.

- Excel Industries targets EBITDA margins of 13% to 15% over the medium term, aiming for a resilient and sustainable business model with operational efficiencies and improved product mix. - FY '25 saw an 18% revenue growth to Rs 978 crores and a strong EBITDA increase of 400%, indicating positive momentum. - Future CAPEX of Rs 200 to 300 crores over 3 years focuses on growth opportunities, especially in specialty chemicals and existing/adjacent products, supported by a strong balance sheet and internal accruals. - Capacity utilization currently at 70%-75%, with a peak effective utilization of 85%-90% before new CAPEX required, supporting scalable growth. - Volume growth is expected to drive revenue increases alongside new product launches, including biocides and contract manufacturing opportunities. - The company plans to maintain a balanced approach to growth with both maintenance and growth CAPEX for sustained profitability and earnings expansion.

- Excel Industries does not follow a traditional order book approach; instead, they focus on a mix of spot market opportunities and positioning for key products. - The company sees good demand for certain biocides and has already expanded capacity in this segment. - They are working on a range of new biocide products to expand this portfolio. - The company anticipates a normal agrochemical sector year in FY '26, supported by forecasts of a normal monsoon in India. - Due to volatile market conditions, Excel prefers to maintain flexibility rather than relying on a fixed order book. - No specific disclosures were made about pending orders or order backlog, reflecting a focus on real-time market dynamics rather than long-term order commitments.